|
已选(0)清除
条数/页： 排序方式： |
| The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study 期刊论文
CHINESE JOURNAL OF CANCER, 2017, 卷号: 36
-
  收藏 | 浏览/下载：25/0 | 提交时间：2020/10/26
SERVICES TASK-FORCE HIGH-RESOLUTION CHINESE WOMEN US METAANALYSIS TRASTUZUMAB STATISTICS EUROPE Breast cancer Stage Molecular subtype Survival China |
| Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏 | 浏览/下载：24/0 | 提交时间：2020/10/26
SOLITARY PLASMACYTOMA RADIATION-THERAPY CLINICAL-FEATURES ONCOLOGY-GROUP SOFT-TISSUE NECK HEAD BONE MULTICENTER GUIDELINES Extramedullary plasmacytoma prognostic factors radiotherapy multiple myeloma |
| Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏 | 浏览/下载：31/0 | 提交时间：2020/10/26
PAINFUL DIABETIC-NEUROPATHY DOUBLE-BLIND PLACEBO PREVENTION MANAGEMENT TRIAL GABAPENTIN PREGABALIN ONCOLOGY TAXANES Duloxetine FACT-Tax Scales paclitaxel peripheral neuropathy |
| Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002-2011) 期刊论文
CHINESE JOURNAL OF CANCER, 2017, 卷号: 36
-
收藏 | 浏览/下载：28/0 | 提交时间：2020/10/26
HOSPITAL COSTS UNITED-STATES DIAGNOSIS CARE Esophageal neoplasms Medical expenditure Diagnosis and treatment China |
| Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey 期刊论文
CHINESE JOURNAL OF CANCER, 2017, 卷号: 36
-
收藏 | 浏览/下载：32/0 | 提交时间：2020/10/26
CARE COSTS SURVIVORS FAMILY MORTALITY ADHERENCE PATIENT CANADA Colorectal neoplasms Direct expenditure Financial burden China |
| Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏 | 浏览/下载：32/0 | 提交时间：2020/10/26
EGFR MUTATIONS GEFITINIB TREATMENT 1ST-LINE TREATMENT OPEN-LABEL RARE MULTICENTER ERLOTINIB GENE CHEMOTHERAPY EFFICACY Non-small cell lung cancer EGFR uncommon mutation target therapy |
